ARCHIVES

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

This article is from The Cancer Letter archive.

Vol. 31 No. 13 | April 1, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: Clarke, Einstein Lead ACCC; Changes At CCSG, Cohen Leaves USC For Childhood Foundation

April 17, 1992

Professional Societies: AACR To Establish A Foundation To fund Outreach, Education

April 23, 1999

In Brief: William Paul to Head AIDS Research Officer; Schachman Is NIH Extramural Obudsman

February 25, 1994

Commission Seeks Comparative Data on Cervical Cancer

August 16, 1991

Executive Summary of Centers, SPOREs Report

February 28, 2003

In Breif: Baltimore Developer Donates $10 Million To Univ. of Maryland Medical System

July 19, 1996